FDA supplemental approval: Acetaminophen AND Codeine Phosphate (REMS)

AI Summary

The FDA approved a supplemental REMS application for acetaminophen and codeine phosphate oral solution (120 mg/5 mL acetaminophen + 12 mg/5 mL codeine phosphate) on 18 June 2026. This is a regulatory action establishing risk management requirements; it does not include clinical trial results or comparative efficacy data.

Plain-language summary

FDA supplemental approval for a Risk Evaluation and Mitigation Strategy (REMS) for an acetaminophen–codeine combination oral solution; regulatory action that affects product labelling and use conditions, not a clinical evidence assessment.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record documents a regulatory action establishing REMS requirements for the product. Clinicians and dispensers must comply with the approved risk management strategy when prescribing or dispensing this acetaminophen–codeine combination. The record itself does not evaluate clinical benefit or harm.

Caveats

• This regulatory record does not contain clinical trial results, efficacy data, or safety outcome numbers.
• No information on the specific REMS requirements or clinical indications is stated in this record.
• The approval of a REMS does not constitute evidence of comparative benefit or superiority over alternatives.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.